Stephen Malherbe Sells 1,000,000 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN – Get Rating) major shareholder Stephen Malherbe sold 1,000,000 shares of the stock in a transaction that occurred on Wednesday, March 8th. The stock was sold at an average price of $11.35, for a total value of $11,350,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Enfusion Price Performance

Enfusion stock opened at $10.35 on Friday. The firm has a 50-day moving average of $11.17 and a 200-day moving average of $11.41. Enfusion, Inc. has a one year low of $7.80 and a one year high of $16.76. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -103.49 and a beta of 0.49.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Lazard Asset Management LLC acquired a new position in Enfusion in the fourth quarter valued at $28,000. UBS Group AG lifted its holdings in Enfusion by 1,189.8% in the fourth quarter. UBS Group AG now owns 6,204 shares of the company’s stock valued at $60,000 after buying an additional 5,723 shares during the period. Barclays PLC increased its stake in Enfusion by 494.6% in the fourth quarter. Barclays PLC now owns 7,248 shares of the company’s stock valued at $70,000 after purchasing an additional 6,029 shares in the last quarter. State of Wyoming increased its stake in Enfusion by 1,048.1% in the fourth quarter. State of Wyoming now owns 9,139 shares of the company’s stock valued at $88,000 after purchasing an additional 8,343 shares in the last quarter. Finally, Citigroup Inc. increased its stake in Enfusion by 24.2% in the first quarter. Citigroup Inc. now owns 7,139 shares of the company’s stock valued at $91,000 after purchasing an additional 1,390 shares in the last quarter. 49.38% of the stock is owned by institutional investors.

Analyst Ratings Changes

ENFN has been the topic of several research analyst reports. The Goldman Sachs Group lowered their price target on Enfusion from $14.00 to $9.50 and set a “neutral” rating on the stock in a research report on Thursday, January 26th. Morgan Stanley upgraded Enfusion from an “equal weight” rating to an “overweight” rating and decreased their target price for the stock from $13.00 to $12.00 in a report on Tuesday, January 3rd. Bank of America cut Enfusion from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $15.00 to $10.00 in a report on Wednesday, January 4th. Finally, Credit Suisse Group lifted their target price on Enfusion to $14.00 in a report on Wednesday, November 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Enfusion has an average rating of “Hold” and an average price target of $12.92.

Enfusion Company Profile

(Get Rating)

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.